

# Definition and Reliability Assessment of Elementary Ultrasonographic Findings in Calcium Pyrophosphate Deposition Disease: A Study by the OMERACT Calcium Pyrophosphate Deposition Disease Ultrasound Subtask Force

Georgios Filippou, Carlo A. Scirè, Nemanja Damjanov, Antonella Adinolfi, Greta Carrara, Valentina Picerno, Carmela Toscano, George A. Bruyn, Maria Antonietta D'Agostino, Andrea Delle Sedie, Emilio Filippucci, Marwin Gutierrez, Mihaela Micu, Ingrid Möller, Esperanza Naredo, Carlos Pineda, Francesco Porta, Wolfgang A. Schmidt, Lene Terslev, Violeta Vlad, Pascal Zufferey, and Annamaria Iagnocco

**ABSTRACT. Objective.** To define the ultrasonographic characteristics of calcium pyrophosphate crystal (CPP) deposits in joints and periarticular tissues and to evaluate the intra- and interobserver reliability of expert ultrasonographers in the assessment of CPP deposition disease (CPPD) according to the new definitions.

**Methods.** After a systematic literature review, a Delphi survey was circulated among a group of expert ultrasonographers, who were members of the CPPD Ultrasound (US) Outcome Measures in Rheumatology (OMERACT) subtask force, to obtain definitions of the US characteristics of CPPD at the level of fibrocartilage (FC), hyaline cartilage (HC), tendon, and synovial fluid (SF). Subsequently, the reliability of US in assessing CPPD at knee and wrist levels according to the agreed definitions was tested in static images and in patients with CPPD. Cohen's  $\kappa$  was used for statistical analysis.

**Results.** HC and FC of the knee yielded the highest interobserver  $\kappa$  values among all the structures examined, in both the Web-based (0.73 for HC and 0.58 for FC) and patient-based exercises (0.55 for the HC and 0.64 for the FC). Kappa values for the other structures were lower, ranging from 0.28 in tendons to 0.50 in SF in the static exercise and from 0.09 (proximal patellar tendon) to 0.27 (triangular FC of the wrist) in the patient-based exercise.

**Conclusion.** The new OMERACT definitions for the US identification of CPPD proved to be reliable at the level of the HC and FC of the knee. Further studies are needed to better define the US characteristics of CPPD and optimize the scanning technique in other anatomical sites. (J Rheumatol First Release March 1 2017; doi:10.3899/jrheum.161057)

## Key Indexing Terms:

CHONDROCALCINOSIS  
KNEE OSTEOARTHRITIS

ULTRASONOGRAPHY  
OSTEOARTHRITIS

From the University of Siena, Siena; Italian Society for Rheumatology (SIR) Epidemiology Unit, Milan; University of Pisa, Pisa; Università Politecnica delle Marche, Jesi; Internal Medicine Division, San Jacopo Hospital, Pistoia; Università degli Studi di Torino, Turin, Italy; University of Belgrade, Belgrade, Serbia; Department of Rheumatology, MC Groep, Lelystad, the Netherlands; APHP, Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Saint-Quentin en Yvelines, France; Division of Musculoskeletal and Rheumatic Diseases, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Mexico City, Mexico; Rehabilitation Clinical Hospital, Cluj-Napoca; Sf. Maria Hospital, Bucharest, Romania; Instituto Poal, University of Barcelona, Barcelona; Department of Rheumatology, Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Deaz and Autónoma University, Madrid, Spain; Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch Berlin, Berlin, Germany; Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark; Lausanne University Hospital, Lausanne, Switzerland.

G. Filippou, MD, PhD, University of Siena; C.A. Scirè, MD, Professor of Rheumatology, SIR Epidemiology Unit; N. Damjanov, MD, PhD, Professor of Rheumatology, University of Belgrade; A. Adinolfi, MD, University of Siena; G. Carrara, MSc, SIR Epidemiology Unit; V. Picerno, MD, University of Siena; C. Toscano, MD, University of Siena; G.A. Bruyn, MD, Professor of Rheumatology, Department of Rheumatology, MC Groep; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; A. Delle Sedie, MD, University of Pisa; E. Filippucci, MD, PhD, Senior Lecturer in Rheumatology, Università Politecnica delle Marche; M. Gutierrez, MD, Division of Musculoskeletal and Rheumatic Diseases, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra; M. Micu, MD, Rehabilitation Clinical Hospital; I. Möller, MD, PhD, Instituto Poal, University of Barcelona; E. Naredo, MD, Department of Rheumatology, Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Deaz and Autónoma University; C. Pineda, MD, PhD, Division of Musculoskeletal and Rheumatic Diseases, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra; F. Porta, MD, Internal

Medicine Division, San Jacopo Hospital; W.A. Schmidt, MD, Professor of Charité University Medicine, Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch; L. Terslev, MD, PhD, Center for Rheumatology and Spine Diseases, Rigshospitalet; V. Vlad, MD, PhD, Sf. Maria Hospital; P. Zufferey, MD, Lausanne University Hospital; A. Iagnocco, MD, Professor of Rheumatology, Università degli Studi di Torino.

Address correspondence to Dr. G. Filippou, Department of Medicine, Surgery and Neurosciences, Rheumatology Section, Policlinico le Scotte, Viale Bracci 16, 53100 Siena, Italy. E-mail: gf.filippou@gmail.com  
Accepted for publication January 13, 2017.

Calcium pyrophosphate deposition disease (CPPD) is one of the most common arthropathies of the elderly. Prevalence rates range from 4% to over 50%<sup>1,2,3,4</sup>, depending on the age of the patient and on the diagnostic method. According to the European League Against Rheumatism (EULAR) recommendations for the diagnosis of CPPD<sup>5</sup>, synovial fluid (SF) analysis is the gold standard for diagnostic purposes, ultrasonography (US) is a promising tool that needs additional studies for demonstrating its involvement in the disease assessment, and conventional radiography is burdened by lower sensitivity compared with SF analysis.

More recently, studies demonstrated the usefulness of US in identifying CPP crystal deposits in the hyaline cartilage (HC) and fibrocartilage (FC) at different joint sites<sup>4,6,7,8,9</sup>. However, a recent systematic literature review emphasized that even if the diagnostic accuracy of US in CPPD is relatively high in all studies, the definitions of the US characteristics of CPP crystal deposits are significantly different<sup>10</sup>. This makes it difficult to compare US results among different studies and makes multicenter studies difficult to perform.

Our aim in this study was to define the ultrasonographic characteristics of CPP deposits in joints and periarticular tissues and to evaluate the intraobserver and interobserver reliability of expert ultrasonographers in the assessment of CPPD according to the new definitions.

## MATERIALS AND METHODS

**Study design and setting.** The Outcome Measures in Rheumatology (OMERACT) US CPPD task force was created and held the first meeting during the American College of Rheumatology congress in 2014. Here, the preliminary results of a systematic literature review and metaanalysis on the use of US in CPPD<sup>10</sup> were presented and the necessity of a validation process in the field was discussed. Following the OMERACT methodology<sup>11</sup>, a Delphi survey on the definition and characteristics of US-detected CPP crystal deposits was circulated. Subsequently, a Web- and a patient-based exercise were performed with the aim of testing the reliability of US in the detection of CPP deposits at different joint and periarticular sites.

Reporting of the results in our manuscript followed previously published guidelines<sup>12</sup>. The study was reported to the local ethics committee and no further approval has been deemed necessary. All patients gave an informed consent before participation in the workshop.

**First step: Delphi survey for defining the US aspect of CPP crystal depositions.** Eighteen rheumatologists from 10 countries (1 from Denmark, 1 from France, 1 from Germany, 6 from Italy, 1 from the Netherlands, 2 from Mexico, 2 from Romania, 1 from Serbia, 2 from Spain, and 1 from Switzerland), who were experts in US and microcrystalline arthritides and members of the OMERACT US CPPD task force, participated in the study.

A preliminary survey was circulated to present the results of the

systematic literature review<sup>10</sup> to all participants and to collect their comments and suggestions on the items to be included in the Delphi survey. Different sets of definitions were included for FC, HC, tendon, and SF to better describe the features of deposits at different anatomical structure levels. For each anatomical site, the following items were defined: the shape, the echogenicity, the localization, and the behavior of the deposits at dynamic scanning.

In the first round, the Delphi survey consisted of 30 statements and the participants rated their level of agreement for each according to a Likert scale (1 = strongly disagree to 5 = strongly agree) and gave their comments. Based on the results and comments obtained, the survey was modified and proposed again to the participants until agreement was reached for at least 1 item at each category. Group agreement was considered achieved with a total cumulative agreement of 75% or more (a score of 4 or 5 in the Likert scale). Statements that did not reach this cutoff were eliminated from the following rounds while statements that achieved agreement were proposed again for voting only in the case of the presence of new statements that were formulated according to the panel's suggestions. If no statement achieved 75% of agreement, those that reached 60% or more plus new statements were proposed again for voting to avoid missing values in the definitions. The Delphi was considered complete when agreement was achieved for all categories of the survey and the panel proposed no further modifications.

**Second step: Web-based exercise.** A pool of 152 US images of the anatomical sites under examination (FC, HC, tendon, SF) were collected in an equally distributed manner by 5 participants who spontaneously offered to contribute. The sample was estimated to be the minimum size to accurately estimate  $\kappa$  values significantly greater than 0.4, setting  $\alpha$  at 0.05 and  $\beta$  at 0.10. The FC images included both menisci of the knees and triangular fibrocartilage of the wrist; HC images were collected from the femoral condyles; tendons included patellar tendon, quadriceps tendon, and Achilles tendon; and SF images were mainly collected from the suprapatellar and lateral recesses of the knee.

Each participant rated the images according to a dichotomous score (presence/absence) by applying the definitions approved in the Delphi survey. The definitions were available above every image to avoid misinterpretations.

Two weeks after the first assessment, all participants rated the same images again to assess the intraobserver reliability.

The whole Delphi process and the Web-based agreement exercise were carried out on a Web-based platform (RedCap). Only the facilitator and the epidemiologists of the study had access to the online data and were responsible for the upload and preparation of the Delphi rounds and the Web-based exercise.

**Third step: Patient-based exercise.** The patient-based exercise was held in Siena, Italy, in December 2015. Nine identical US machines were used (MyLabSeven, Esaote) equipped with a 3-13 MHz linear probe. In all machines, the same settings were used. The settings were created to better enhance calcific depositions and were tested and approved by the experts before the workshop. Each sonographer was allowed to modify only the basic functions (depth, gain, time gain control, frequency) to obtain the best possible image for CPP identification according to the patient's physical characteristics.

Nine patients [4 with a diagnosis of CPPD and 5 with osteoarthritis (OA) according to SF examinations performed within 6 months before the workshop] were invited to participate. Fifteen ultrasonographers out of the 18 included in the panel participated in the exercise. Each sonographer examined the right knee and the right wrist of each subject and rated the presence/absence of CPP deposits in the HC, meniscal FC, patellar and quadriceps tendons, SF (if present) of the knee and triangular FC, and SF (if present) of the wrist. Three independent rheumatologists, experts in US and members of the local organizing committee, assisted the ultrasonographers during the procedure by collecting the data sheets and organizing and timing the shifts.

The US examination was performed according to a standardized

sequence, using techniques already described in the literature for the identification of CPP deposits<sup>13,14,15</sup>. The posterior portion of the HC was overlooked to prevent patients' discomfort from having to roll over several times; they were generally old and had functional limitation from the disease. The knee tendons were examined with the joint in complete extension, in semiflexion, and maximal flexion by transverse and longitudinal scans. SF was examined in all anterior joint recesses with the quadriceps tendon under contraction. At the wrist joint, SF was examined at the dorsal recesses with both longitudinal and transverse scanning. The triangular FC of the wrist was examined by sliding the probe over the structure, without lifting it, from the dorsal to the palmar aspect in longitudinal scanning and from proximal to distal for the transverse scanning. In all cases, dynamic scanning could be used if considered necessary (for example, flexion-extension of the knee or medial-lateral motion of the wrist).

Each sonographer had 10 min to assess the requested sites. After time expiration, the sonographer moved to the next station until every sonographer examined all patients. Power Doppler (PD) examination was not necessary for CPPD identification, but PD examination was allowed upon sonographers' judgment to better identify anatomical landmarks (vessels) or avoid pitfalls/artifacts (posterior enhancement of vessels that could mimic CPPD). Each sonographer rated the images according to a dichotomous score (presence/absence) by applying the definitions approved in the Delphi survey. The definitions were printed and provided to each sonographer before the exercise to avoid misinterpretations.

The procedure was repeated twice with the same patients the same day (morning and afternoon) to assess the intraobserver reliability.

**Statistical analysis.** Intra- and interobserver reliability were calculated using the  $\kappa$  coefficient. Intraobserver reliability was assessed by Cohen's  $\kappa$ . Interobserver reliability was studied by calculating the mean  $\kappa$  on all pairs (i.e., Light's  $\kappa$ )<sup>16</sup>. Kappa coefficients were interpreted according to Landis and Koch<sup>17</sup>. Kappa values of 0–0.20 were considered poor, 0.20–0.40 fair, 0.40–0.60 moderate, 0.60–0.80 good, and 0.80–1.00 excellent. The percentage of observed agreement (i.e., percentage of observations that obtained the same score) and prevalence of the observed lesions were also calculated.

Analyses were performed using R Statistical Software (Foundation for Statistical Computing).

## RESULTS

**Delphi survey.** All participants responded to all rounds of the Delphi survey (100% response rate). At the preliminary round, the definitions extrapolated from the systematic literature review were elaborated and presented to the panel divided by anatomical site and US characteristics as described above (Supplementary Table 1 is available with the online version of this article).

After the collection of the panel's comments, the first Delphi round included 94 statements for voting. At the first round, 16 statements reached agreement and 24 statements were modified and/or added according to the comments received by the panelists, and were proposed again for voting in the second Delphi round. At the second round, 7 more statements reached agreement for a total of 23 statements, covering all aspects of US characteristics of all anatomical sites, except for the echogenicity of CPP deposition in the SF. At the third round, only 2 modified definitions regarding this aspect were proposed and finally agreement was also achieved on it. A summary of the results and the course of the Delphi survey can be seen in Supplementary Table 2, available with the online version of this article. The final definitions of the OMERACT US task force for the US aspect and characteristics of CPPD are represented in Figure 1.

**Web-based interobserver and intraobserver reliability exercises.** All participants successfully completed both rounds of the Web-based exercise. Interreader variability, including both rounds, ranged from 0.28 for tendons (fair agreement) to 0.73 achieved for HC (good agreement). Intraobserver reliability was higher in all sites varying from a minimum value of 0.64 for SF (good agreement) to a

**Table 1.** Interobserver results of the Web-based and patient-based exercise. Strength of agreement: < 0.20 poor, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80 substantial, 0.81–1.00 excellent.

Site	Mean Prevalence %		Mean Observed Agreement		Mean Cohen's $\kappa$	
	First Round	Second Round	First Round	Second Round	First Round	Second Round
<b>Web-based exercise</b>						
Fibrocartilage	61.1	58.6	0.80	0.79	0.58	0.58
Hyaline cartilage	59.1	61.7	0.87	0.87	0.73	0.73
Tendons	41.8	47.2	0.64	0.65	0.28	0.31
Synovial fluid	41.2	41.5	0.76	0.75	0.50	0.47
<b>Patient-based workshop</b>						
All	44.4	45.7	0.72	0.72	0.44	0.45
Knee	43.6	44.2	0.74	0.76	0.47	0.52
Menisci	70.4	75.6	0.86	0.88	0.65	0.64
Medial meniscus	65.9	70.4	0.88	0.9	0.72	0.74
Lateral meniscus	74.8	80.7	0.84	0.85	0.57	0.48
Synovial fluid	34.1	25.2	0.59	0.67	0.09	0.12
Tendon	28.4	30.1	0.69	0.7	0.25	0.3
Quadriceps tendon	46.7	53.3	0.56	0.59	0.13	0.19
Proximal patellar tendon	13.3	16.3	0.79	0.79	0.09	0.19
Distal patellar tendon	25.2	20.7	0.72	0.74	0.31	0.25
Hyaline cartilage	45.2	43	0.79	0.77	0.58	0.55
Wrist	47.4	50.7	0.65	0.59	0.31	0.2
Triangular fibrocartilage	64.4	65.9	0.67	0.61	0.27	0.15
Synovial fluid	30.4	35.6	0.63	0.57	0.15	0.1

Table 2. Intraobserver results of the Web-based and patient-based exercise. Strength of agreement: < 0.20 poor, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80 substantial, 0.81–1.00 excellent.

Site	Mean Prevalence	Mean Prevalence, Range of %	Agreement Range	Mean Cohen's $\kappa$	Cohen's $\kappa$ Range
Web-based exercise					
Fibrocartilage	59.9	43.1–80	0.806–1.000	0.8	0.596–1.000
Hyaline cartilage	60.4	48.7–78.2	0.795–1.000	0.85	0.544–1.000
Tendon	39.1	21.4–93.8	0.667–1.000	0.76	0.201–1.000
Synovial fluid	44.5	0–65.2	0.818–1.000	0.64	0.522–1.000
Patient-based workshop					
All	45.1	24.1–70.4	0.704–0.938	0.63	0.4–0.854
Knee	43.9	26.2–65.1	0.73–0.952	0.65	0.442–0.881
Menisci	73	55.6–97.2	0.778–1.000	0.73	0–1.000
Medial meniscus	68.2	55.6–94.4	0.778–1.000	0.78	0–1.000
Lateral meniscus	77.8	55.6–100	0.778–1.000	0.7	–0.125 to 1.000
Synovial fluid	29.6	0–61.1	0.556–1.000	0.41	–0.125 to 1.000
Tendon	29.2	3.7–59.3	0.63–0.926	0.44	0–0.743
Quadriceps tendon	50	5.6–83.3	0.333–0.889	0.28	–0.286 to 0.78
Proximal patellar tendon	14.8	0–33.3	0.556–1.000	0.47	–0.174 to 1.000
Distal patellar tendon	23	5.6–61.1	0.444–1.000	0.44	–0.154 to 1.000
Hyaline cartilage	44.1	27.8–61.1	0.667–1.000	0.68	0.308–1.000
Wrist	49.1	13.9–88.9	0.556–0.944	0.5	–0.091 to 0.889
Triangular fibrocartilage	65.2	27.8–100	0.556–1.000	0.47	0–1.000
Synovial fluid	33	0–83.3	0.444–1.000	0.36	–0.125 to 1.000

maximum value of 0.85 for HC (very good agreement).

*Patient-based interobserver and intraobserver reliability.* The patient-based exercise was successfully completed in 2 rounds of about 3 and a half h each, 1 in the morning and 1 in the afternoon of the same day. Interobserver reliability, including both rounds, ranged from 0.09 (poor agreement) for the patellar tendon to 0.74 (good agreement) for the medial meniscus. Intraobserver reliability was higher in all sites and varied from 0.28 for the quadriceps tendon (fair) to 0.78 for the medial meniscus (good). Detailed results of all rounds of the patient-based exercise are presented in Table 1 (interobserver) and Table 2 (intraobserver).

## DISCUSSION

US has been increasingly used during the last decade for the diagnosis of patients with CPPD, as highlighted by a recent systematic literature review<sup>10</sup>. Further, the utility of US in assessing patients with suspected CPPD has been recognized by the EULAR recommendations, which acknowledged US as a promising tool for the diagnosis of the disease<sup>5</sup>. US is a feasible, safe, and available tool used by the rheumatologist in bedside settings. However, agreed-upon definitions for identifying CPPD by US are lacking<sup>10</sup>.

The OMERACT US group acknowledged those gaps regarding the use of US in CPPD, and in 2014 the OMERACT US subtask force on CPPD was created to proceed with the standardization of the technique in that disease. According to the OMERACT procedures, the first step was to create the definitions for the US identification of CPPD through a Delphi exercise. Division of the definitions into 4 sections (shape,

form, localization, and behavior in dynamic scanning) could allow the inclusion of all previously published definitions, even if incomplete. Then, the panel's expertise could fulfill the missing statements to achieve homogeneous and complete definitions for each anatomical site.

Before final approval of the definitions that took place during the Siena workshop, some questions related to Delphi results were raised and discussed. The major concern was whether those definitions could be applied to all joints or only to the knee joint because most of the papers that were used for retrieving the first set of statements were dealing with the knee joint<sup>7,13,14,15,18</sup>. The panel was not able to answer this question and agreed that the patient-based exercise could come up with some elements to address this aspect. Another point of discussion was the final definition of tendon deposition of CPP crystals because not all experts agreed to include the word "multiple" in the shape category. After discussing this issue, the panel conveyed that multiple depositions could increase the specificity of the finding because "single spots" could be indicative of many different kinds of pathology, and the final definition was thus approved entirely.

The Web-based reliability exercise demonstrated good results for the deposits at the level of the HC, SF, and FC while tendon assessment needs further evaluations. The good results globally obtained in all fields demonstrate consistency in the application of the new definitions, even though the interpretation of the US findings may be different among the ultrasonographers. For the patient-based exercise, 9 volunteers participated. Four of them had crystal-proven CPPD and





Structure	Shape	Echogenicity	Localization	Behavior at Dynamic Scanning	Example
<b>Fibrocartilage</b>	Deposits of variable shape.	Hyperechoic (similar to the bone cortex echogenicity).	Localized within the fibrocartilage structure.	Remain fixed and move together with the fibrocartilage during dynamic assessment (i.e., joint movement and probe compression).	
<b>Hyaline cartilage</b>	Deposits varying in size and shape.	Hyperechoic (similar to the bone cortex echogenicity) that do not create posterior shadowing.	Localized within the hyaline cartilage.	The deposits remain fixed and move together with the hyaline cartilage (i.e., joint movement and probe compression).	
<b>Tendon</b>	Multiple, linear (parallel to the tendon fibrillar structure and not in continuity with the bone profile) deposits.	Hyperechoic (in relation to the tendon echogenicity) that generally do not create posterior shadowing. The deposits maintain their high degree of echogenicity even at very low levels of gain and are not affected by anisotropy as the surrounding tendon.	Localized within the tendon.	Remain fixed and move together with the tendon during movement and probe compression.	
<b>Synovial fluid</b>	Deposits of variable size (from punctuate to large).	Hyperechoic (similar to the bone cortex echogenicity) that generally do not create posterior shadowing.	Localized within the synovial fluid.	Are mobile according to joint movement and probe pressure.	

Figure 1. Outcome Measures in Rheumatology definitions.

5 had OA, but with no examination that could rule out the presence of CPP crystals in the joints. The observers were blinded to any clinical or laboratory findings. The mean prevalence of the findings indicating CPPD in the joints of the volunteers was adequate and allowed the drawing of safe conclusions on the results, which were not biased by a lack or abundance of US findings. During the patient-based exercise,  $\kappa$  values changed considerably compared with the  $\kappa$  values obtained at the Web-based exercise.

The results of the Web-based and the patient-based exercises raise some considerations. First, as stated by the different results obtained at the FC level of knee and wrist, the new definitions may be applied only at the knee level, while they need to be retested in other FC sites. This discrepancy may be due to either local technical difficulties at the triangular fibrocartilage of the wrist or to the presence of local abnormalities that could mimic the presence of CPP deposits and create misinterpretations. This aspect needs further investigation.

Second, tendons and SF yielded the lowest values of inter-observer agreement both in static and in the patient-based exercise. This may be related to the difficult applicability of

the definitions and the need for a standardized scanning technique. Further, regarding tendons, in this workshop we decided not to include the Achilles tendon and the plantar fascia in our assessment, despite the high specificity of CPPD at these tendons<sup>10</sup>. This choice was made to reduce the discomfort of the patient during the examination, considering that to properly assess the Achilles tendon and the plantar fascia, the patient must roll over on the examination bed. We preferred to prevent this discomfort and also to save the time that the patient would use to take the correct position. Perhaps assessing the Achilles tendon would provide higher  $\kappa$  values, being a more familiar site for CPPD evaluation, but it would not reflect the reliability of assessing other tendons, less frequently involved by CPPD. Further studies are needed to better identify the features that indicate the presence of CPP deposition in those 2 structures.

To our knowledge, this is the first attempt by an international panel to create US CPPD diagnostic criteria following the rigorous OMERACT methodology. These new OMERACT definitions yielded good results in terms of reliability in the assessment of the knee HC and FC. Results at the level of other anatomical sites proved not to be satis-

factory. However, the knee joint, and especially the medial meniscus, appears to be the most frequently involved site in CPPD<sup>6</sup>, and thus of interest in terms of US reliability. Taking this into account, the OMERACT US definitions for identification of CPP crystal deposits can be used at the knee level (HC and FC assessments) and may be a good support for disease diagnosis. The use of agreed and reliable definitions is of great interest, particularly in a multicenter setting. Further studies are needed to better define the US appearance of CPP deposits and the most appropriate scanning technique in anatomical sites other than the knee, and then to test their diagnostic accuracy for CPPD identification.

## APPENDIX 1.

List of study collaborators. OMERACT US in CPPD Group: Anthony Reginato, Mario Enrique Diaz Cortes, Tomas Cazenave, Daryl MacCarter, Florentin Verzu, Mohamed Atia Mortada, Teodore Serban, Iulia Satulu, Gael Monderde, Frederich Glandjbakhch, Marco A. Cimmino, Bruno Frediani, and Luca M. Sconfienza.

## ACKNOWLEDGMENT

The authors appreciate the unconditional support of Esaote for the patient-based exercise and the Italian Society for Rheumatology for making available the RedCap platform for this workshop.

## ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

## REFERENCES

1. Ciano G, Bortoluzzi A, Govoni M. Epidemiology of gout and chondrocalcinosis. *Reumatismo* 2012;63:207–20.
2. Salaffi F, De Angelis R, Grassi W; MArche Pain Prevalence; INvestigation Group (MAPPING) study. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. *Clin Exp Rheumatol* 2005;23:819–28.
3. Musacchio E, Ramonda R, Perissinotto E, Sartori L, Hirsch R, Punzi L, et al. The impact of knee and hip chondrocalcinosis on disability in older people: the ProVA Study from northeastern Italy. *Ann Rheum Dis* 2011;70:1937–43.
4. Filippou G, Adinolfi A, Cimmino MA, Scirè CA, Carta S, Lorenzini S, et al. Diagnostic accuracy of ultrasound, conventional radiography and synovial fluid analysis in the diagnosis of calcium pyrophosphate dihydrate crystal deposition disease. *Clin Exp Rheumatol* 2016;34:254–60.
5. Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. *Ann Rheum Dis* 2011;70:563–70.
6. Filippou G, Filippucci E, Tardella M, Bertoldi I, Di Carlo M, Adinolfi A, et al. Extent and distribution of CPP deposits in patients affected by calcium pyrophosphate dihydrate deposition disease: an ultrasonographic study. *Ann Rheum Dis* 2013;72:1836–9.
7. Gutierrez M, Di Geso L, Salaffi F, Carotti M, Girolimetti R, De Angelis R, et al. Ultrasound detection of cartilage calcification at knee level in calcium pyrophosphate deposition disease. *Arthritis Care Res* 2014;66:69–73.
8. Zufferey P, Valcov R, Fabreguet I, Dumusc A, Omoumi P, So A. A prospective evaluation of ultrasound as a diagnostic tool in acute microcrystalline arthritis. *Arthritis Res Ther* 2015;17:188.
9. Filippou G, Bozios P, Gambera D, Lorenzini S, Bertoldi I, Adinolfi A, et al. Ultrasound detection of calcium pyrophosphate dihydrate crystal deposits in menisci: a pilot in vivo and ex vivo study. *Ann Rheum Dis* 2012;71:1426–7.
10. Filippou G, Adinolfi A, Iagnocco A, Filippucci E, Cimmino MA, Bertoldi I, et al. Ultrasound in the diagnosis of calcium pyrophosphate dihydrate deposition disease. A systematic literature review and a meta-analysis. *Osteoarthritis Cartilage* 2016;24:973–81.
11. Boers M, Kirwan JR, Gossec L, Conaghan PG, D'Agostino MA, Bingham CO 3rd, et al. How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0. *J Rheumatol* 2014;41:1025–30.
12. Kottner J, Audigé L, Brorson S, Donner A, Gajewski BJ, Hróbjartsson A, et al. Guidelines for Reporting Reliability and Agreement Studies (GRRAS) were proposed. *J Clin Epidemiol* 2011;64:96–106.
13. Filippou G, Frediani B, Gallo A, Menza L, Falsetti P, Baldi F, et al. A “new” technique for the diagnosis of chondrocalcinosis of the knee: sensitivity and specificity of high-frequency ultrasonography. *Ann Rheum Dis* 2007;66:1126–8.
14. Frediani B, Filippou G, Falsetti P, Lorenzini S, Baldi F, Acciai C, et al. Diagnosis of calcium pyrophosphate dihydrate crystal deposition disease: ultrasonographic criteria proposed. *Ann Rheum Dis* 2005;64:638–40.
15. Filippucci E, Riveros MG, Georgescu D, Salaffi F, Grassi W. Hyaline cartilage involvement in patients with gout and calcium pyrophosphate deposition disease. An ultrasound study. *Osteoarthritis Cartilage* 2009;17:178–81.
16. Light RJ. Measures of response agreement for qualitative data: some generalizations and alternatives. *Psychol Bull* 1971;76:365–77.
17. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159–74.
18. Filippucci E, Scirè CA, Delle Sedie A, Iagnocco A, Riente L, Meenagh G, et al. Ultrasound imaging for the rheumatologist. XXV. Sonographic assessment of the knee in patients with gout and calcium pyrophosphate deposition disease. *Clin Exp Rheumatol* 2010;28:2–5.